Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc.

NASDAQ:VKTX

Overview | Financials
Company Name Viking Therapeutics, Inc.
Symbol VKTX
Currency USD
Price 66.73
Market Cap 7,393,417,080
Dividend Yield 0%
52-week-range 8.28 - 99.41
Industry Biotechnology
Sector Healthcare
CEO Dr. Brian Lian Ph.D.
Website https://www.vikingtherapeutics.com

An error occurred while fetching data.

About Viking Therapeutics, Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat

Related Stocks

XBiotech Inc. logo

XBiotech Inc.

XBIT

7.06 USD

Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc.

ORMP

2.49 USD

Talkspace, Inc. logo

Talkspace, Inc.

TALK

1.96 USD

Profound Medical Corp. logo

Profound Medical Corp.

PROF

7.72 USD

Harrow Health, Inc. logo

Harrow Health, Inc.

HROW

45.14 USD

Fusion Pharmaceuticals Inc. logo

Fusion Pharmaceuticals Inc.

FUSN

21.55 USD

Beyond Air, Inc. logo

Beyond Air, Inc.

XAIR

0.419 USD

Financials

Numbers are in millions USD

Numbers are in millions USD